205 related articles for article (PubMed ID: 31072232)
1. Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers.
Huiying Z; Guangying C; Shiyang Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):981-989. PubMed ID: 31072232
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antidiabetic activity of some new chromonyl-2,4-thiazolidinediones.
Ceylan-Ünlüsoy M; Verspohl EJ; Ertan R
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):784-9. PubMed ID: 20687791
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and in-vivo hypoglycemic evaluation of novel non - TZD'S in a type - 2 diabetic model.
Jadhav R; Gupta-Rajoria R; Pal T; Subramanian RC
Med Chem; 2013 Feb; 9(1):104-11. PubMed ID: 22762162
[TBL] [Abstract][Full Text] [Related]
8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
[TBL] [Abstract][Full Text] [Related]
11. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
Arlt W; Neogi P; Gross C; Miller WL
J Mol Endocrinol; 2004 Apr; 32(2):425-36. PubMed ID: 15072549
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of novel l-phenylglycine derivatives as potential PPARγ lead compounds.
Liu J; Su X; Li H; Fan L; Li Y; Tang X; Yan J; Chen X; Chen F; Liu J; Yang D
Bioorg Med Chem; 2018 Aug; 26(14):4153-4167. PubMed ID: 30001846
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
14. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antidiabetic activity of morpholinothiazolyl-2,4-thiazolidindione derivatives.
Ezer M; Yıldırım LT; Bayro O; Verspohl EJ; Dundar OB
J Enzyme Inhib Med Chem; 2012 Jun; 27(3):419-27. PubMed ID: 21740103
[TBL] [Abstract][Full Text] [Related]
16. [Design, synthesis and antidiabetic activity of novel tetrahydrocarboline PPAR regulators].
Peng K; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2014 Apr; 49(4):490-6. PubMed ID: 24974466
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and glucose uptake activity of some novel glitazones.
Kar K; Krithika U; Mithuna ; Basu P; Santhosh Kumar S; Reji A; Prashantha Kumar BR
Bioorg Chem; 2014 Oct; 56():27-33. PubMed ID: 24927033
[TBL] [Abstract][Full Text] [Related]
18. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
19. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Koyama H; Boueres JK; Han W; Metzger EJ; Bergman JP; Gratale DF; Miller DJ; Tolman RL; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
Bioorg Med Chem Lett; 2003 May; 13(10):1801-4. PubMed ID: 12729668
[TBL] [Abstract][Full Text] [Related]
20. The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism.
Shao H; Li D; Yang Y; Guo HF; Liu ZY; Si SY; Yang Z; Li ZR
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):282-9. PubMed ID: 19663652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
